title: Regadenoson: a focused update.
abstract: Since its approval by the Food and Drug Administration in 2008, regadenoson has become the most commonly used vasodilator in the United States. Previous reviews have summarized the pre-clinical and clinical data on the use of regadenoson for myocardial perfusion imaging (MPI). Since then, data have emerged on the safety of this agent in special groups of patients such as those with chronic kidney disease, airway disease (asthma and chronic obstructive pulmonary disease), and liver disease. There has also been recent interest in the use of regadenoson in hybrid protocols with exercise as a way to improve patient tolerance and image quality. Finally, although regadenoson was approved for clinical use based on the agreement rate of regadenoson MPI and adenosine MPI with regards to perfusion abnormalities, data are now available on the prognostic data derived from regadenoson MPI. We will briefly summarize these recent reports here in a focused update on the use of regadenoson for MPI.
authors.affiliation: Division of Cardiovascular Diseases, University of Alabama at Birmingham, 318 LHRH, 1900, University Blvd, Birmingham, AL 35294, USA.
authors.forename: Gopal
authors.initials: G
authors.lastname: Ghimire
authors.forename: Fadi G
authors.initials: FG
authors.lastname: Hage
authors.forename: Jaekyeong
authors.initials: J
authors.lastname: Heo
authors.forename: Ami E
authors.initials: AE
authors.lastname: Iskandrian
mesh_terms: D003324:Coronary Artery Disease / Q000000981:diagnostic imaging*; D019317:Evidence-Based Medicine; D005080:Exercise Test / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D055414:Myocardial Perfusion Imaging / Q000009:adverse effects / Q000379:methods*; D011687:Purines / Q000009:adverse effects*; D011720:Pyrazoles / Q000009:adverse effects*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D015899:Tomography, Emission-Computed, Single-Photon / Q000009:adverse effects / Q000379:methods*; D014665:Vasodilator Agents / Q000009:adverse effects
chemical_list: D011687:Purines; D011720:Pyrazoles; D014665:Vasodilator Agents; C430916:regadenoson